1-3 of 3
Anjali Advani
Close
Sort by
Journal Articles

Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL

Yaqi Zhao, A. Douglas Laird, Kathryn G. Roberts, Rolla Yafawi, Hagop Kantarjian, Daniel J. DeAngelo, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan O’Brien, Elias Jabbour, Ryan D. Cassaday, Melanie R. Loyd, Scott Olsen, Geoffrey Neale, Xueli Liu, Erik Vandendries, Anjali Advani, Charles G. Mullighan
Journal: Blood Advances
Blood Adv (2024) 8 (12): 3226–3236.
https://doi.org/10.1182/bloodadvances.2023012430
Published: 2024
Includes: Supplemental data
Journal Articles

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Brian T. Hill, Shuo Ma, Clive S. Zent, Andrea M. Baran, Danielle S. Wallace, Anjali Advani, Allison Winter, Jane Winter, Leo Gordan, Reem Karmali, Jane L. Liesveld, Deborah A. Mulford, Chris Rowland, Andrew Bui, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Jonathan W. Friedberg, Paul M. Barr
Journal: Blood Advances
Blood Adv (2024) 8 (2): 378–387.
https://doi.org/10.1182/bloodadvances.2023010693
Published: 2024
Journal Articles

Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab

Clinical Trials & Observations
Talha Badar, Aniko Szabo, Anjali Advani, Martha Wadleigh, Shukaib Arslan, Muhammad Ali Khan, Ibrahim Aldoss, Caitlin Siebenaller, Elizabeth Schultz, Mehrdad Hefazi, Rory M. Shallis, Ilana Yurkiewicz, Nikolai Podoltsev, Anand A. Patel, Emily Curran, Suresh Balasubramanian, Jay Yang, Ryan J. Mattison, Madelyn Burkart, Shira Dinner, Michaela Liedtke, Mark R. Litzow, Ehab Atallah
Journal: Blood Advances
Blood Adv (2020) 4 (10): 2308–2316.
https://doi.org/10.1182/bloodadvances.2019001381
Published: 2020
Includes: Supplemental data